CERS — Cerus Corporation

Cerus Corporation (CERS) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenues: $233.8 million for 2025, a record and up 16% from 2024.
• Product Revenue: Increased 14% year-over-year, exceeding guidance of $202 million to $204 million.
• Product Gross Margin: 51.5% in Q4 2025, down from 53.9% in Q4 2024, impacted by higher production costs and inflation.
• GAAP Net Loss: $2.2 million for Q4; $15.6 million for the full year, a 25% improvement from the previous year.
• Non-GAAP Adjusted EBITDA: $3.4 million for Q4 and $9.5 million for the full year, marking the second consecutive year of positive adjusted EBITDA.
• Cash Position: Ended 2025 with approximately $83 million in cash and short-term investments.

2. Strategic Updates and Business Highlights

• INTERCEPT Blood System: Approximately 3 million INTERCEPT-treated blood components produced in 2025, benefiting around 600,000 patients globally.
• INT200 Device: Launched in Europe with positive customer feedback; PMA application for U.S. expected mid-2026.
• Group Purchasing Agreement: Signed with Blood Centers of America (BCA), expected to enhance market penetration and streamline sales processes.
• International Growth: Strong performance in EMEA, with double-digit growth in platelet and plasma kit sales; Germany identified as a $30 million annual opportunity for platelets.

3. Forward Guidance and Outlook

• 2026 Product Revenue Guidance: Expected between $224 million to $228 million, representing a 9% to 11% increase from 2025.
• IFC Revenue Guidance: Anticipated between $20 million to $22 million, reflecting a 20% to 30% year-over-year growth.
• Market Penetration: IFC market adoption estimated at 7% at the end of 2025, with expectations of over 50% by year-end 2026.

4. Bad News, Challenges, or Points of Concern

• Gross Margin Pressure: Continued impact from import tariffs and inflationary pressures, with expectations for margins to remain in the low 50% range for 2026.
• R&D Funding: Anticipated tapering of government reimbursed R&D expenses as BARDA contract nears expiration in September 2026.
• Regulatory Risks: Uncertainty around the timing of CE marking for red blood cells in Europe, with potential delays pushing approval to 2027.

5. Notable Q&A Insights

• BCA Agreement: Expected to significantly enhance penetration in the U.S. platelet market, leveraging BCA's supply chain and educational resources.
• EMEA Growth: Strong performance driven by the rollout of INT200 and ongoing penetration in Germany, with the INITIATE study expected to support increased adoption.
• Middle East Opportunities: Notable growth potential in Saudi Arabia and other Gulf states, influenced by U.S. standards for blood products.
• Cash Flow Expectations: Continued investment in inventory to support growth, but operating cash flow is expected to remain positive as the business scales.

Overall, Cerus Corporation demonstrated strong growth in 2025, with strategic initiatives aimed at expanding market share and enhancing product offerings, while also facing challenges related to margins and regulatory timelines.